Analytical Data
-
基因名
HLA-A*03:01&B2M&KRAS G12C(VVVGACGVGK) Monomer
- Application
-
别名
HLA-A*0301 & B2M & KRASG12C (VVVGACGVGK)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
NP_002107.3 (G25-T305)&P61769
-
表达区间
NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVVGACGVGK
-
分子量
66 kDa, 55 kDa, 41-43 kDa, 34 kDa, 27 kDa and 11 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*03:01/B2M/KRAS G12C (VVVGACGVGK) monomeric recombinant protein focuses on the interactions between human leukocyte antigen (HLA), beta-2-microglobulin (B2M), and mutated KRAS protein, which is a critical component of various malignancies, particularly pancreatic and colorectal cancers. KRAS G12C is a common mutation that leads to aberrant signaling pathways, promoting uncontrolled cell growth and survival. Understanding the immune response to this specific mutant peptide, presented by the HLA-A*03:01 molecule, is essential for developing targeted immunotherapies. The recombinant protein allows for the investigation of T-cell recognition and binding affinity, providing insights into how the immune system can be harnessed to set off a therapeutic response against KRAS-driven tumors. This research not only elucidates the intricacies of antigen presentation but also aids in the design of vaccines and personalized treatments that can enhance anti-tumor immunity, thereby improving clinical outcomes for patients with KRAS G12C-associated cancers.
